Inhibition of the expression of ornithine decarboxylase by haloperidol in difluoromethylornithine-resistant leukemia cells

Biochemical Pharmacology

Volumn 52, Issue 9, 1996, Pages 1393-1397

  Flamigni, Flavio ^a   Stanic, Ivana ^a   Stefanelli, Claudio ^a   Muscari, Claudio ^a   Giaccari, Antonella ^a   Rossoni, Carmen ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cell proliferation; gene expression; haloperidol; leukemia L1210 cells; ornithine decarboxylase; receptors

Indexed keywords

3 (4 FLUOROBENZOYL)PROPIONIC ACID; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG METABOLITE; EFLORNITHINE; HALOPERIDOL; MESSENGER RNA; METAPHIT; ORNITHINE DECARBOXYLASE; PENTOXYVERINE; SIGMA RECEPTOR LIGAND; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INDUCTION; LEUKEMIA CELL LINE; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THYMOCYTE;

EID: 0030575948     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00471-6     Document Type: Article

References (32)

1. 1. Iishi H, Baba M, Tatsuta M, Okuda S and Taniguchi H, Inhibition by the dopamme antagonist haloperidol of experimental carcinogenesis induced by azoxymethane in rat colon. Cancer Res 51: 6150-6152, 1991.
2. 2. Frussa-Filho R, do Carmo Monteiro M, Soares CGS and Decio RC, Effects of haloperidol, bromocriptine and amphetamine on the development of Ehrich ascites carcinoma in mice. Pharmacology 45: 58-60, 1992.
3. 3. Silver MA, Yang ZW, Ganguli R, Nimgaonkar VL, An inhibitory effect of psichoactive drugs on a human neuroblastoma cell line. Biol Psychiat 35: 824-826, 1994.
4. 4. Vilner BJ, de Costa BR and Bowen WD, Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15: 117-134, 1995.
5. 5. Nahas GG, Desoize B and Leger C, Effects of psychotropic drugs on DNA synthesis in cultured lymphocytes. Proc Soc Exp Biol Med 160: 344-348, 1979.
6. 6. Roudebush RE, Berry PL, Layman NK, Butler LD and Bryant HU, Dissociation of immunosuppression by chlorpromazine and trifluoroperazine from pharmacologie activities as dopamine antagonists, Int J Immunopharmacol 13: 961-968, 1991.
7. 3H] ( + )-pentazocine binding sites on cells of the immune system. J Neuroimmunol 35: 153-166, 1991.
8. 8. Holson RR, Webb PJ, Grafton TF and Hansen DK, Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. Teratology 50: 125-136, 1994.
9. 9. Patel AJ, Barochoosky O and Lewis PD, Psychotropic drugs and brain development: effects on cell replication in vivo and in vitro. Neuropharmacology 20: 1243-1249, 1981.
10. 10. Pegg AE, Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759-774, 1988.
11. 1. Heby O and Persson L, Molecular genetics of polyamine synthesis in eukaryotic cells. Trends Biochem Sci 15: 153-158, 1990.
12. 12. Abrahamsen MS, Li R-S, Dietrich-Goetz W and Morris DR, Multiple DNA elements responsible for transcriptional regulation of the ornithine decarboxylase gene by protein kinase A. J Biol Chem 267: 18866-18873, 1992.
13. 13. Bello-Fernandez C, Packham G and Cleveland JL, The ornithine decarboxylase gene is a transcriptional target of c-myc. Proc Natl Acad Sci USA 90: 7804-7808, 1993.
14. 14-Wrighton C and Busslinger M, Direct transcriptional stimulation of the ornithine decarboxylase gene by fos in PC12 cells but not in fibrobtasts. Mol Cell Biol 13: 4657-4669, 1993.
15. 15. Auvinen M, Paasinen A, Andersson LC and Hölttä E, Ornithine decarboxylase activity is critical for cell transformation. Nature 360: 355-358, 1992.
16. 16. Clifford A, Morgan D, Yuspa SH, Peralta Soler A and Gilmour S, Role of ornithine decarboxylase in epidermal tumorigenesis. Cancer Res 55: 1680-1686, 1995.
17. 17. Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawinski JA and O'Brien TG, Increased frequence of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 55: 4205-4209, 1995.
18. 18. Persson L, Holm I and Heby O, Regulation of ornithine decarboxylase mRN A translation by polyamines. Studies using a cell-free system and a cell line with an amplified ornithine decarboxylase gene. J Biol Chem 263: 3528-3533, 1988.
19. 19. Flamigni F, Campana G, Carboni L, Guarnieri C and Spampinato S. Zinc is required for the expression of ornithine decarboxylase is a difluoromethylornithine-resistant cell line. Biochem J 299: 515-519, 1994.
20. 20. Stefanelli C, Ferrari F, Rossoni C, Flamigni F and Caldarera CM, Zinc can influence ornithine decarboxylase activity in rat thymus cells. Aminoacids 4: 53-61, 1993.
21. 21. Hyttinen J-M, Halmekyto M, Alhonen L and Jänne J, Levels of ornithine decarboxylase genonic sequences, heterogeneous nuclear RNA and mRNA in human myeloma cells resistant to a-difluoromethylornithine. Biochem. J 278: 871-874, 1991.
22. 22. Chomczynsky P and Sacchi N, Single-step method of RNA isolation by acid guanidinium thiocianate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
23. 23. Walkner JM, Bowen WD, Walkner FO, Matsumoto RR, De Costa B and Rice KC, Sigma receptors: biology and function. Pharmacol Rev 42: 355-402, 1990.
24. 24-Bowen WD, Moses EL, Tolentino PJ and Walkner JM, Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors. Eur J Pharmacol 111: 111-118, 1990.
25. 25. Thomas GE, Szucs M, Mamone JY, Bem WT, Rush MD, Johnson FE and Coscia CJ, Sigma and opioid receptors in human brain tumors. Life Sci 46: 1279-1286, 1990.
26. 26. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE and Coscia CJ, Overexpression of sigma receptors in non-neural human tumors. Cancer Res 51: 6558-6562, 1991.
27. 27. Vilner BJ, John CS and Bowen WD, Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent cell lines. Cancer Res 55: 408-413, 1995.
28. 28. Wolfe Jr. SA, Kulsakdinun C, Bathaglia G, Jaffe JH and De Sonza EB, Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. J Pharmacol Exp Ther 247: 1114-1119, 1988.
29. 29. Brent PJ and Pang GT, σ Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 278: 151-160, 1995.
30. 30. De Coster MA, Klette KL, Knight ES and Tortella FC, σ Receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 671: 45-53, 1995.
31. 31. Moshier JA, Malecka-Panas E, Geng H, Dosescu J, Tureand J, Skunka M and Majumdar APN, Ornithine decarboxylase transformation of NIH/3T3 cells is mediated by altered epidermal growth factor receptor activity. Cancer Res 55: 5358-5365, 1995.
32. 32. Thomas TJ, Gunnia UB, Seibold JR and Thomas T, Defective signal-transduction pathways in T-cells from autoimmune MRL-lpr/lpr mice are associated with increased polyamine concentrations. Biochem J 311: 175-182, 1995.